Current Partners

Currently Developing
(sofpironium bromide) For Hyperhidrosis in Japan
Exclusive License - Mar. 2015
Leading Skincare Company in S. Korea
Strategic Investor
Collaboration - Feb. 2013
Kaken Pharmaceutical Co., Ltd.

Currently Developing BBI-4000 (novel 'soft-anticholinergic') For Hyperhidrosis in Japan

Kaken (Tokyo Stock Exchange: 4521) is a Japanese specialty pharmaceutical company with a strong presence in the market of dermatology (antifungals) and orthopedics. The company’s primary areas of R&D focus include inflammation, immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain and antifungals.


Leading Skincare Company in S. Korea & Strategic Investor

AMOREPACIFIC, based in Seoul, South Korea, is one of the leading cosmetic and aesthetics companies in Asia, with annual turnover of approximately $3 billion. AMOREPACIFIC Ventures, the corporate venture fund of AMOREPACIFIC, focuses on innovative technologies in beauty and aesthetic area.